

CLINICAL TRIAL PROTOCOL

A contemporary neuroscience approach compared to biomedically focused education combined with symptom-contingent exercise therapy in people with chronic whiplash associated disorders: a randomized controlled trial protocol[☆]



Iris Coppieters^{a,b,c,*}, Ward Willaert^{a,c,1}, Dorine Lenoir^{a,c,1}, Mira Meeus^{c,d,1}, Barbara Cagnie^c, Kelly Ickmans^{a,b,e,1}, Anneleen Malfliet^{a,b,e,1}, Lieven Danneels^c, Brenda De Petter^f, Jo Nijs^{a,b,1}

^a Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy (KIMA), Faculty of Physical Education & Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium

^b Department of Physical Medicine and Physiotherapy, University Hospital Brussels, Brussels, Belgium

^c Department of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

^d Department of Rehabilitation Sciences and Physiotherapy (MOVANT), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

^e Research Foundation-Flanders (FWO), 1090 Brussels, Belgium

^f Sint-Jozefkliniek, Campus Bornem (AZ Rivierenland), Bornem, Belgium

Received 23 January 2020; received in revised form 29 July 2020; accepted 23 September 2020

Available online 10 October 2020

KEYWORDS

Chronic whiplash associated disorders;
Contemporary neuroscience;
Exercise therapy;
Stress management;
Treatment protocol

Abstract

Background: To address the need for a better treatment of chronic whiplash associated disorders (WAD), a contemporary neuroscience approach can be proposed.

Objective: To examine the effectiveness of a contemporary neuroscience approach, comprising pain neuroscience education, stress management, and cognition-targeted exercise therapy versus conventional physical therapy for reducing disability (primary outcome measure) and improving quality of life and reducing pain, central sensitization, and psychological problems (secondary outcome measures) in people with chronic WAD.

[☆] Trial registration number: ClinicalTrials.gov – NCT03239938 (<https://clinicaltrials.gov/ct2/show/NCT03239938>).

* Corresponding author at: Vrije Universiteit Brussel, Faculty of Physical Education and Physiotherapy, Department of Physiotherapy, Human Physiology and Anatomy (KIMA), Laarbeeklaan 103 – building F, 1090 Brussels, Belgium.

E-mail: iris.coppieters@vub.be (I. Coppieters).

¹ Member of the Pain in Motion International Research Group (www.paininmotion.be).

Methods: The study is a multi-center, two-arm randomized, controlled trial with 1-year follow-up and will be performed in two university-based and one regional hospital. People with chronic WAD ($n = 120$) will be recruited. The experimental group will receive pain neuroscience education followed by cognition-targeted exercise therapy, and stress management. The control group will receive biomedically focused education followed by graded and active exercise therapy focusing on muscle endurance, strength, and flexibility, and ergonomic principles. The treatment will have a duration of 16 weeks. Functional status (Neck Disability Index) is the primary outcome measure. Secondary outcome measures include quality of life, pain, central sensitization, and psychological and socio-economic factors. In addition, electroencephalography will measure brain activity at rest and during a conditioned pain modulation paradigm. Assessments will take place at baseline, immediately post-treatment and at 6 and 12 months follow-up.

Conclusions: This study will examine whether a contemporary neuroscience approach is superior over conventional physical therapy for improving functioning, quality of life, and reducing pain, central sensitization, and psychological problems in people with chronic WAD.

© 2020 Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia. Published by Elsevier Editora Ltda. All rights reserved.

Introduction

Whiplash injury is one of the most common traffic-related injuries.¹ Approximately 50% of people who encounter a whiplash injury will continue to experience ongoing disability and pain 1 year after the injury.² Poor treatment responses and treatment of patients with chronic whiplash associated disorders (WAD) remain a challenge for health care professionals.^{3–6}

In chronic WAD, substantial evidence supports the presence of central sensitization.⁷ Central sensitization encompasses various related dysfunctions of the central nervous system, all contributing to increased responsiveness to a variety of stimuli.⁸ In many people with chronic WAD, central sensitization and the resulting exaggerated pain and disability dominate the clinical picture over the cervical dysfunctions. It is known that people will move differently when they are in pain⁹ and the brain does not always require nociception – anticipation of pain suffices – to change its way of controlling body movement.¹⁰ Therefore, it is warranted to reconceptualize pain (e.g. pain does not per se result from tissue damage) before moving to more active treatment approaches.^{11,12} This could be addressed by reducing the threat value of pain by means of pain neuroscience education (PNE).¹³

PNE is effective for improving maladaptive pain beliefs and decreasing disability and pain in various chronic pain disorders,^{13–17} including chronic WAD.¹³ However, PNE is not a stand-alone treatment and the effect sizes are small to moderate, but it is a crucial first step to prepare patients for a time-contingent, cognition-targeted approach to physical activity and exercise therapy.

A dysfunctional stress response and posttraumatic stress symptoms can be present in patients with chronic WAD.^{18–21} Posttraumatic stress symptoms have a negative influence on the recovery and severity of WAD complaints.²² Also, pain and stress are closely interconnected²³ and stress is a sustaining factor of central sensitization.²⁴ Hence, addressing

stress via a stress management intervention integrated in the treatment for chronic WAD is important in the contemporary neuroscience approach accounting for central sensitization.²⁴

Once the patient has adopted adaptive beliefs, the next step can be taken: dynamic and functional exercise therapy. This therapy should be cognition-targeted including exercises that are performed in a time-contingent manner.²⁵ A previous randomized controlled trial showed that PNE combined with cognition-targeted exercise therapy is superior over biomedically focused education and pain-contingent exercise therapy in patients with nonspecific chronic spinal pain.²⁶ While few promising studies have examined a combined approach of PNE with specific exercise therapy,^{14,16,26,27} none focused specifically on patients with chronic WAD.

To our knowledge, this will be the first sufficiently powered randomized controlled trial to examine the effectiveness of a contemporary neuroscience approach (i.e. PNE combined with stress management and cognition-targeted exercise therapy) versus conventional physical therapy for various important outcome measures in people with chronic WAD. The primary objective is to examine whether the contemporary neuroscience approach is more effective than conventional physical therapy in reducing disability (primary outcome measure) and improving quality of life, socio-economic factors, and illness perceptions, and decreasing pain, central sensitization, posttraumatic stress symptoms, pain catastrophizing, and pain-related fear (secondary outcome measures) in people with chronic WAD.

Methods

Trial design and setting

A multi-center, randomized controlled trial, will be performed in the University Hospital Brussels and University Hospital Ghent and a regional hospital (Sint-Jozefkliniek

Campus Bornem). The trial is designed as a parallel group, two-arm, superiority trial with a 1:1 allocation ratio. The study protocol is designed following the standard protocol items for randomized interventional trials (SPIRIT)²⁸ and trial results will be reported according to the CONSORT guidelines.²⁹

Participants and recruitment procedure

One-hundred-twenty participants with chronic WAD will be recruited. Inclusion and exclusion criteria are listed in [Table 1](#). Participants will be recruited from the hospitals of the participating universities (UZ Brussels; UZ Ghent) and a secondary care hospital (Sint-Jozefkliniek) as well as other hospitals and universities, via social media, primary care practices, pharmacies, and publications from patients support groups. Recruitment will also take place via radio, newspapers, magazines, symposia, health insurance companies, and district health centers.

Sample size calculation

Sample size calculation was performed with G*Power 3.1.9.2 focusing on the primary outcome measure (functional status) and primary endpoint (6 months follow-up) based on the therapy effects on functional status (difference in functional status between baseline and 6 months follow-up in a previous randomized controlled trial²⁶ with 2 balanced treatment arms and comparable control and intervention therapies in patients with chronic spinal pain (NCT03239938)), and accounting for a 25% loss to follow-up after 6 months (based on the loss to follow-up percentage of the finished trial).²⁶ Calculations were based on two-tailed testing with $\alpha = 0.05$ and a desired power of 0.80, with a partial eta squared = 0.032, effect size = 0.18, allocation ratio (N2/N1) = 1, resulting in 60 patients in the experimental group and 60 patients in the control group. The total sample size is 120 people with chronic WAD. Currently, 71 patients have been included in the study and 34 patients have completed the study.

Randomization and allocation procedure

Participants are randomized in a 1:1 ratio between intervention and control arms using a stratified permuted block allocation with stratification factor being treatment center and a block size of four. Randomization lists will be prepared separately for the 3 treatment centers by an independent investigator of the Biostatistics Unit who has no other study involvement. Only 1 independent researcher, not involved in recruitment, assessments, and treatment, will perform the randomization of participants after baseline assessment, and will conceal the randomization from patients and the other researchers using opaque, closed envelopes.

Details of the experimental and control interventions

All participants will receive 18 therapy sessions over a period of 16 weeks ([Table 2](#)). The physical therapists will have a

master's degree and will be intensively trained in performing the experimental or control treatment by physical therapists experienced in the experimental (AM, JN) or control therapy (DL, WW). Every 8 months, a refresher course will be organized.

Experimental intervention – contemporary neuroscience approach

The contemporary neuroscience approach will comprise 3 interactive PNE sessions (1 group session followed by 2 individual sessions), and 15 sessions of cognition-targeted exercise therapy and stress management.^{12,25} The education covers the physiology of the nervous system in general and of the pain system in particular. The content and pictures of the educational sessions are based on current knowledge of pain science and pain education books,^{30,31} and the PNE content is adapted to the chronic WAD condition. Additionally, the physiology of the stress response systems and the relationship between stress and pain modulation will be explained during the PNE sessions as first educational part of the stress management.

After the PNE group session, patients will be asked to read an informational leaflet about the (neuro)physiology of pain³¹ and afterwards watch an online educational PowerPoint about the (neuro)physiology of pain at home. A more detailed description of how PNE will be provided is presented elsewhere.³²

The cognition-targeted dynamic and functional exercise therapy will consist of 15 individual sessions. The main principles of this exercise therapy are: (1) all exercises should be performed in a time-contingent ("perform this exercise 10 times, regardless of the pain") rather than a symptom-contingent way ("stop or adjust the exercise when it hurts"); (2) goal setting is done together with the patient, focusing on functionality instead of pain relief; (3) the therapist should continuously assess and challenge the patient's cognitions, beliefs, and perceptions about the pain and the anticipated outcome of each exercise to change maladaptive cognitions and perceptions into positive ones;²⁵ (4) exercises should be individually tailored and gradually progress toward more feared, avoided, challenging, complex, and functional movements and activities.¹²

An activity form will be used to ask participants to indicate which movements and activities are feared/avoided/painful. This form will be used by the therapist to obtain a hierarchy in fearful, avoided, and/or painful movements/activities and will allow the therapist to individually tailor the exercises and create a progression in the offered exercises, movements, and activities. Communication techniques are crucial and will be aligned with the PNE content. Several exercises used in the exercise program will also be practiced in a functional way by the patient at home. Further details regarding the cognition-targeted exercise approach are described elsewhere.¹²

The experimental intervention will also include stress management ([Table 3](#)). The first step will consist of the *education phase* as described above. The therapist will ask during the individual education session whether the patient experiences stress and to what extent, and the stress coping strategies will be questioned. Subsequently, the therapist will explain different stress management techniques

Table 1 Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> • Having experienced a whiplash trauma (i.e. neck pain resulting from a motor vehicle crash or traumatic event) diagnosed by a doctor (grade II to III as defined by the Quebec Task Force scale^{75,76}) which causes pain for at least 3 months with a mean pain frequency of 3 days per week or more • Moderate to severe pain-related disability, established by a score of $\geq 15/50$ on the Neck Disability Index (NDI)³⁶ • Women and men aged between 18 and 65 years • Being a native Dutch speaker • Not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation 	<ul style="list-style-type: none"> • Suffering from epilepsy, a rheumatic, endocrinological, psychiatric, or cardiovascular disorder • History of specific spinal surgery (e.g. surgery for spinal stenosis) • History of neck or shoulder surgery in the past 3 years • Loss of consciousness after the whiplash trauma for longer than 1 minute • Being pregnant or having given birth in the preceding year • Neuropathic pain with diagnosis of nerve injury • Chronic widespread pain syndromes • Neuroscientific based therapy in patient history, and concomitant therapies

Table 2 Organization of therapeutic sessions.

Weeks	Experimental treatment	Control treatment
Weeks 1-3	Session 1-3: Pain neuroscience education (one group session, informational leaflet and home-based online presentation, and 2 individual (one-on-one) sessions) Frequency: 1 session per week. Duration: group education session: 1 hour. Individual education sessions: 30 minutes.	Session 1-3: Biomedically focused neck school education (one group session, informational leaflet and home-based online presentation, and 2 individual (one-on-one) sessions)
Weeks 4-16	Session 4-18: 15 one-on-one cognition-targeted time-contingent exercise therapy sessions and stress management. Frequency: In the first 2 weeks, the exercise sessions will be provided with a frequency of 2 times a week and the other weeks with a frequency of 1 time a week Duration of sessions: 30 minutes	Session 4-18: 15 one-on-one symptom-contingent graded and active exercise therapy sessions.

namely Jacobson's progressive relaxation therapy, Visualization, and Mindfulness. Next, the participant will choose one of these techniques to try at home in a quiet environment. Eventually the patient will choose one technique to perform the further stress management protocol.

The next phase (i.e. *initiation phase*) consists of the try out session of the stress management technique(s) of the patient's choice at home and the identification of stressors that are relevant for the patient's life. Subsequently, the therapist will discuss patients' perceptions about stress and explain various stress coping strategies. The patient will determine which coping strategy will be applied for each listed stressor. Afterwards, the participant will receive a stress reaction record to fill out at home. Next, the patient will practice the stress management technique during quiet moments during the *skills training phase*. Afterwards, the

patient will perform the stress management technique during increasingly challenging and stressful situations (i.e. the *confrontation phase*).

Control intervention – biomedically focused education followed by exercise therapy

Patients will participate in interactive educational sessions (biomedically focused neck school education) comprising 1 group session followed by 2 individual sessions. The education covers the normal course of neck pain, the anatomy, physiology, and biomechanics of the cervical spine, common mechanical causes of neck pain, the load-tolerance model, the importance of ergonomics, intradiscal pressure, and joint forces, lifting techniques, and the purpose and value of stretching and strength, endurance, and fitness

Table 3 Organization and content of the stress management program included in the experimental intervention.

Education phase	Session 1:
Week 1-3 (session 1-3)	<ul style="list-style-type: none"> • Education session in group • Explanation about stress, stress mechanisms/responses, relationship between stress and pain
Initiation phase	Session 2-3:
Week 2-5 (session 2-8)	<ul style="list-style-type: none"> • Individual education sessions • The therapist explains the 3 different stress management techniques and the patient chooses one technique to try at home. • The aim of stress management (i.e. to learn how to cope better with daily stressors and to reduce the negative consequences of stress) will be explained.
Skills training phase	Session 2-3:
Week 6-11 (session 8-13)	<ul style="list-style-type: none"> • List relevant stressors of the patient (identification of stressors) • The therapist checks the patients' perceptions about stress • The therapist identifies the current stress coping strategies of the patient and explains 3 different stress coping strategies (avoiding, changing, and learning to handle the stressor(s)).
Confrontation phase	Session 4-8:
Week 11-15 (session 13-17)	<ul style="list-style-type: none"> • The patient tries different techniques => choice of technique • The therapist explains the use of the stress reaction record and gives the record to the patient to fill out at home to obtain insight in the thoughts, emotions, and coping strategies in response to stressors. • The therapist evaluates the stress reaction record. • Skills training • Patient practices stress management technique during quiet non-stressful moments • The therapist evaluates the stress reaction record. • The patient performs the stress management technique during increasingly challenging and stressful situations (gradual exposure). • The therapist guides the patient throughout the different phases. • The therapist evaluates the stress reaction record. • The therapist receives the stress reaction record and gives advice regarding further application of stress management.
End therapy	<ul style="list-style-type: none"> • The stress management focuses on the patient practicing the stress management technique at home with regular evaluation moments during the therapy sessions. • During the therapy sessions, the stress reaction record is evaluated and the therapist guides and discusses the stress management program performed at home by the patient.
Week 16 (session 18)	

training. Ergonomic principles like computer work and lifting techniques will be discussed. In addition, self-care training and the advice to remain active will be provided.

At the end of the first session, patients will be asked to first read an information leaflet and afterwards watch an online educational PowerPoint about the content of the neck school at home.

The neck school will prepare the patients for a symptom-contingent, biomedical approach to daily activity and exercise therapy. An individually supervised, patient-specific, graded, and active exercise therapy program will be performed during the next 13 weeks in 15 individual sessions. The symptom-contingent exercise program will

focus on treating biomedical dysfunctions of the spine (e.g., mobility, strength) and general fitness exercises, with an evolution toward functional activities and physically demanding tasks while keeping the spine in physiologically neutral positions. Different therapeutic goals will be pursued depending on what emerges from clinical reasoning. The exercise program will consist of different types of exercises including warm-up, muscular endurance, strength, ergonomic, and flexibility exercises.

An activity form will be used. A graded progression of the 'dosage' of the symptom-contingent exercises will be emphasized. When the participant reports pain during or after an exercise, the intensity or duration of the exer-

cise will be reduced. Several exercises used in the exercise program will also be practiced at home.

Treatment contrast

The main difference between the groups is the treatment of cognitive aspects of pain, stress management, targeting the brain, and accounting for central sensitization in the contemporary neuroscience group (biopsychosocial, time-contingent), which will not be applied in the control group (biomedical, symptom-contingent). Both interventions consist of an equal number of sessions and equal contact time with the therapist, and home exercises.

Primary and secondary outcome measures and assessment points

Outcome measures will be assessed consistent with IMM-PACT/OMERACT recommendations,³³ and will be collected at baseline, after treatment completion, and at 6 months (primary endpoint and intermediate follow-up) and 12 months (long-term follow-up) after the end of treatment (Fig. 1). All assessors will be extensively trained.

Personal, demographic, and socio-economic characteristics will be collected at baseline. After treatment completion and at 6 months follow-up, all baseline tests will be performed again and all questionnaires will be completed. The 1 year follow-up will only include completing the questionnaires. Patient-reported outcomes will be completed online using LimeSurvey.

Primary outcome measure

Functional status was chosen as primary outcome measure. Individuals with chronic pain consider increased ability to function an important treatment objective.³⁴ The Neck Disability Index (NDI) is the most commonly used self-report outcome measure for neck pain.³⁵ The NDI will be used to investigate pain-related disability levels (0-50).³⁶ The NDI is sensitive, valid, and reliable to assess self-reported disability.^{37,38}

Secondary outcome measures

For the evaluation of *health-related quality of life*, the 36-item Short-Form Health Survey Questionnaire (SF-36) will be used.^{39,40} The SF-36 has been shown to have good reliability and validity in patients with chronic pain.⁴¹

Current, average, and worst pain intensity will be assessed using an 11-point (0–10) numeric pain rating scale (NPRS). The NPRS has fair to moderate test-retest reliability in patients with neck pain.⁴² Also, pain frequency and its location will be assessed.

Central sensitization. The central sensitization inventory (CSI) will be completed. This questionnaire measures self-reported symptoms related to central sensitization and its overlapping symptoms in people with chronic pain (0-100).^{43–46} The CSI has good internal consistency, good discriminative power, and excellent test-retest reliability.⁴³

Endogenous pain modulation will be assessed by evaluating (1) electrical detection thresholds (EDTs) and

electrical pain thresholds (EPTs),⁴⁷ (2) endogenous pain facilitation,^{48,49} and (3) endogenous pain inhibition.^{49,50} *Electrical detection and electrical pain thresholds.* EDTs and EPTs will be measured unilaterally at the sural nerve of the leg and at the median nerve of both arms with a Digitimer DSA7 constant current stimulator (Digitimer, Hertfordshire, United Kingdom). The felt pad electrode for stimulation of the sural nerve will be placed 2 cm posterior to the lateral malleolus, at the innervation area of the sural nerve,⁵¹ and will be placed on the skin overlying the median nerve for stimulation of the median nerve. The cathode of this electrode will be placed 5 cm proximally from the wrist while the anodal electrode will be placed 3 cm distally from the cathode.⁵² The order of test locations will be randomized. Each stimulus will be a constant current rectangular pulse train consisting of 5 pulses⁵³ delivered at a frequency of 250 Hz, each lasting 0.5 ms^{54,55} (inter stimulus interval = 3.5 ms, total duration of 5 pulse train = 20 ms).

Stimulation will start at 0 mA and will be gradually increased using steps of 0.5 mA^{56,57} until the patient is experiencing a faint sensation (EDT) and until the stimulus is experienced as unpleasant (EPT).⁵⁸ The mean EDT and EPT of 3 measurements with 30 seconds in between will be used for further analyses. EPTs is a reliable measure.⁵⁹

Endogenous pain facilitation. Secondly, to examine endogenous pain facilitation, temporal summation will be assessed by delivering 20 electrical stimuli⁵⁶ at the previously determined EPT intensity,⁵⁸ with an inter-stimulus interval of 0.5 sec. The participant will be asked to give a verbal numeric rating scale (VNRS) score ranging from 0 (no pain) to 10 (worst possible pain)⁵⁶ after the 1st, the 10th, and the 20th stimulus. After this testing, there will be a rest period of 2 minutes.

Endogenous pain inhibition. Thirdly, the efficacy of endogenous pain inhibition will be assessed with the conditioned pain modulation (CPM) paradigm. The cold pressor task will be used as conditioning stimulus and electrical stimulation as test stimulus.⁶⁰ Electrical stimulation will consist of 20 stimuli (250 Hz, train of five), with a variable interstimulus interval of 8–12 seconds, at 1.4 times EPT⁶¹ at the sural nerve and at the median nerve bilaterally.⁵⁸ These stimuli will be given before (baseline condition) and during the application of the conditioning stimulus. Participants will be asked to immerse their hand up to the wrist in a bath (VersaCool, Thermo Fisher Scientific, USA) with circulating cold water maintained at 12 °C for 3 minutes (conditioned stimulus).^{58,62}

After applying the CPM paradigm at one body site the procedure will be performed at the second and third body site with a 3 minute interval in between each test location.

For the baseline and CPM condition and for each test location, participants will be asked to score the overall experience of the electrical stimuli using a VNRS from 0 (no pain) to 10 (worst possible pain), after having received the 20 stimuli. CPM is a reliable measure with intersession reliability varying from fair to excellent.⁶³

Quantitative electroencephalography recordings during rest and during the CPM paradigm. Quantitative scalp electroencephalography (EEG) to examine *brain activity* will be recorded continuously using the eego sports system (ANT neuro, Enschede, The Netherlands) at a sampling rate of




Figure 1 Flow diagram of the study.

2000 Hz from 32 active surface Sn electrodes in a head-cap with unipolar montage following the standard 10/20 recording system. The ground electrode is located in the active-shield cap fronto-centrally between the FPz and the Fz electrode. The reference electrode is located at CPz.

During the recordings, participants will be instructed to close their eyes, avoid blinking, and try to sit as still as possible. During the first 5 minutes of the EEG recording, resting-state EEG activity will be measured. Afterwards, EEG will be collected during the assessment of CPM.

Table 4 Additional protocol items following the standard protocol items for randomized interventional trials (SPIRIT statement).**Adherence**

The degree of treatment adherence will be measured with the amount and frequency of therapy sessions (out of 18) completed by the participants in combination with performance of the home exercises. Treatment adherence will be measured by discussing with the patients during prespecified treatment sessions which and how many home exercises they performed. The patients will also provide this information via a home exercise diary that is used to assess therapy compliance. Additionally, the therapist will ask during the first individual education session whether the patient has read the online PowerPoint education and the educational information leaflet at home. Detailed information from each participant about number, dates, and frequency of completed sessions, and if applicable reason and moment of dropout or loss to follow-up will be recorded.

Concomitant care and interventions

Participants in both groups will be allowed to take their usual medication but not to follow other concomitant physical and psychological therapy interventions during the 16 weeks of treatment. Treatments received outside of the trial treatment will be recorded during the treatment and follow-up phase. If surgery needs to take place during the treatment period, the participant will be excluded, and this will be documented.

Data collection method: retention

To promote participant retention and completion of follow-up assessments, the assessor will contact the participants prior to the assessments, reminding them of the upcoming data collection and the incentive they will receive when completing the assessments. Specifically, participants will receive a gift voucher at the 6 months follow-up assessments and a second gift voucher at the 1 year follow-up assessment when completing all assessments of the respective test moment. If the participant is willing to complete the online questionnaires at home but is not willing to complete the laboratory-based experimental measurements at the 6 months follow-up and/or the test moment immediately after the treatment, the participant is allowed to only complete the questionnaires. However, completing all assessments is encouraged, and the reasons for not completing assessments are noted. Additionally, at the end of each therapy session the next therapy session is already scheduled, and the laboratory-based assessments will be scheduled sufficiently ahead of time.

Statistical analyses

Data analysis will be conducted based on intention to treat principles. Intention to treat analysis is generally favored because it avoids bias associated with non-random loss of participants and corresponds to analyzing the groups exactly as randomized regardless of whether they received the randomized treatment.⁷⁷ To avoid selection bias, we will perform an 'as randomized' analysis which retains participants in the group to which they were originally allocated. To prevent attrition bias, outcome data obtained from all participants will be included in the data analysis. These two conditions (i.e., all participants, as randomized) define our intention to treat analysis, which is recommended as the preferred analysis strategy.⁷⁷ We will consult the Biostatistics Unit of Ghent University when performing these analyses. We will record and report reasons for missing data for each randomization group. Additionally, pre-specified subgroup analyses will be performed. Factors associated with poor outcome and factors associated with clinically important changes in the outcome measures following treatment will be assessed. The trial is not specifically powered for these subgroup analyses. The study is powered for the primary outcome parameter 'pain-related disability' at 6 months follow-up. Interim analyses have not been performed.

Ethics

Approval to conduct this study was granted by the ethics committee of the University Hospital Brussels (2016/388), Ghent University Hospital (2017/0850), and Sint-Jozefkliniek Campus Bornem (1811CP175). This study was registered with the ClinicalTrials.gov Identifier No. NCT03239938. The trial will be conducted in compliance with the Declaration of Helsinki and Good Clinical Practice. Participants will give their written informed consent prior to participation in the study.

Monitoring

The study will monitor adverse events during the treatment (e.g. hospitalization) and by asking questions to the patients including questions about changes in medication use immediately after the end of the treatment. Furthermore, at 6 and 12 months follow-up, questions concerning medication use, hospitalization, emergency visits, overnight stays (e.g. in rehabilitation centers), and consultations with medical specialists and healthcare providers for physical and/or psychological complaints will be asked.

Data security and management plan

Participant data are stored on a secure database in accordance with the General Data Protection Regulations (2018). All personal identifiable information and clinical trial data will be separated. Data are de-identified and a unique trial identification number will be used, and the link between personal identifiable data and this identification number will be stored securely and separately from trial data (pseudonymisation). All personal information collected from the patients will be stored and analyzed confidentially. Electronic records of the data will be generated and saved to the University servers which are automatically backed up daily. Responses of the online questionnaires completed using LimeSurvey will be saved on a secure password protected University server which will only be accessible by the researchers.

The responsible person to preserve the trial data during and at least 10 years after completion of the trial will be the project coordinator (IC), who will be supervised by the principal investigator (JN). In case the project coordinator does not continue working at the Vrije Universiteit Brussel or Ghent University in the 10 years after completion of the trial, the principal investigator will take over the role as responsible person. Along with the coordinator and the principal investigator, project team members will have responsibility for study-wide data management, data quality assurance, and security.

Self-reported psychological correlates. The Pain Catastrophizing Scale, which has good psychometric quality, will be used to assess *catastrophic thoughts and feelings about pain*.⁶⁴

The illness perception questionnaire-revised will be used to measure *the illness perceptions* of the patient. This questionnaire is reliable and has good construct validity and internal consistency.⁶⁵

The Impact of Event Scale-Revised (IES-R) will be used to assess *symptoms of posttraumatic stress*.⁶⁶ The IES-R is a self-report measure of current subjective distress in response to a specific traumatic event.⁶⁷

The Pain Anxiety Symptoms Scale (PASS-20) will be used to evaluate *pain-related fear, pain-related anxiety responses, and fear-avoidance behavior*.^{68,69} The PASS-20 has good predictive and construct validity and strong internal consistency and reliability.⁶⁹

Socio-economic outcomes. *Health care use and health-related costs* will be evaluated using the combination of 2 self-reported valid questionnaires: (1) the Medical Consumption Questionnaire,⁷⁰ a generic instrument for measuring direct medical costs of a patients' total medical consumption, and (2) the Productivity Cost Questionnaire⁷¹ to obtain data regarding the indirect costs outside health care, but related to the disease.⁷²

Blinding

Participants will not know if they receive the experimental or control intervention, however, they will be aware of the intervention received. Additionally, outcome assessors and the statistician will be blind to the treatment groups for all primary and secondary outcomes. After each post-treatment assessment moment, the success of assessor blinding will be examined by asking whether the assessor thinks the patient received the experimental or control intervention, including the percentage of certainty. The same method will be used to assess the success of patient blinding for treatment group. The therapists providing the experimental intervention will not be involved in providing the control intervention, and vice versa.

Additional protocol items following the SPIRIT statement

Information concerning adherence, concomitant care, and interventions, retention, statistical analyses, ethics, the data security and management plan, and monitoring can be found in [Table 4](#).

Statistical analyses

Baseline data will be analyzed to determine descriptive statistics for the outcome measures. Analyses will be performed to unravel relationships between functional status, pain, psychological correlates, and central sensitization. A linear mixed models analysis will be used to evaluate and compare therapy effects. Data analysis will be conducted following intention to treat principles. Effect sizes, 95% confidence intervals, and statistically and clinically signif-

icant differences will be calculated. We will consider a between-group difference of 3.5 points on disability (NDI) and 1 point on pain intensity (NPRS) to be minimal clinically important.^{73,74}

Discussion

This study will provide novel data on the effectiveness of a contemporary neuroscience approach compared to biomedically focused education followed by symptom-contingent exercise therapy on key patient-centered outcome measures and various measures of central sensitization in people with chronic WAD.

Important study strengths include the multi-center study design, blinded outcome assessments up to 1-year follow-up, the validated and reliable outcome measures, the randomized controlled study design, and the balanced treatment arms. This trial may provide new and improved treatment guidelines for health care professionals for the treatment of people with chronic WAD, and may be used as a basis for recommendations to health authorities.

Conflict of interest

The authors have no conflicts of interest. Jo Nijs has co-authored a Dutch book for clinicians on pain neuroscience education and has authored a Dutch book for clinicians on central sensitization in clinical practice, but the royalties for those books are collected by the Vrije Universiteit Brussel and not him personally.

Acknowledgements

The authors gratefully acknowledge Roos Colman from the Biostatistics Unit of Ghent University for the preparation of the randomization lists. This work was supported by the Research Foundation Flanders (FWO), Belgium [grant number G007217N]. The funder will have no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, approval, or submission of any manuscript that will emerge from this study.

References

1. Holm LW, Carroll LJ, Cassidy JD, Hogg-Johnson S, Cote P, Guzman J, et al. The burden and determinants of neck pain in whiplash-associated disorders after traffic collisions: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther.* 2009;32(2 Suppl):S61-S69.
2. Carroll LJ, Hogg-Johnson S, Cote P, van der Velde G, Holm LW, Carragee EJ, et al. Course and prognostic factors for neck pain in workers: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *Spine (Phila Pa 1976).* 2008;33(4 Suppl):S93-S100.
3. Sterling M. Physiotherapy management of whiplash-associated disorders (WAD). *J Physiother.* 2014;60(1):5-12.
4. Rushton A, Wright C, Heneghan N, Eveleigh G, Calvert M, Freemantle N. Physiotherapy rehabilitation for whiplash associated disorders II: a systematic review and meta-analysis of randomized controlled trials. *Br Med J Open.* 2011;1(2):e000265.

5. Michaleff ZA, Maher CG, Lin CW, Rebeck T, Jull G, Latimer J, et al. Comprehensive physiotherapy exercise programme or advice for chronic whiplash (PROMISE): a pragmatic randomised controlled trial. *Lancet*. 2014;384(9938):133–141.
6. Nijs J, Ickmans K. Chronic whiplash-associated disorders: to exercise or not? *Lancet*. 2014;384(9938):109–111.
7. Van Oosterwijck J, Nijs J, Meeus M, Paul L. Evidence for central sensitization in chronic whiplash: a systematic literature review. *Eur J Pain*. 2013;17(3):299–312.
8. Nijs J, Van Houdenhove B, Oostendorp RA. Recognition of central sensitization in patients with musculoskeletal pain: application of pain neurophysiology in manual therapy practice. *Man Ther*. 2010;15(2):135–141.
9. Hodges PW, Tucker K. Moving differently in pain: a new theory to explain the adaptation to pain. *Pain*. 2011;152(3 Suppl):S90–S98.
10. Tucker K, Larsson AK, Oknelid S, Hodges P. Similar alteration of motor unit recruitment strategies during the anticipation and experience of pain. *Pain*. 2012;153(3):636–643.
11. Caneiro JP, Bunzli S, O'Sullivan P. Beliefs about the body and pain: the critical role in musculoskeletal pain management. *Braz J Phys Ther*. 2020.
12. Malfliet A, Kregel J, Meeus M, Cagnie B, Roussel N, Dolphens M, et al. Applying contemporary neuroscience in exercise interventions for chronic spinal pain: treatment protocol. *Braz J Phys Ther*. 2017;21(5):378–387.
13. Van Oosterwijck J, Nijs J, Meeus M, Truijens S, Craps J, Van den Keybus N, et al. Pain neurophysiology education improves cognitions, pain thresholds, and movement performance in people with chronic whiplash: a pilot study. *J Rehabil Res Dev*. 2011;48(1):43–58.
14. Moseley GL. Joining forces – combining cognition-targeted motor control training with group or individual pain physiology education: a successful treatment for chronic low back pain. *J Man Manipul Ther*. 2003;11(1):88–94.
15. Moseley GL, Nicholas MK, Hodges PW. A randomized controlled trial of intensive neurophysiology education in chronic low back pain. *Clin J Pain*. 2004;20(5):324–330.
16. Moseley L. Combined physiotherapy and education is efficacious for chronic low back pain. *Aust J Physiother*. 2002;48(4):297–302.
17. Louw A, Diener I, Butler DS, Puentedura EJ. The effect of neuroscience education on pain, disability, anxiety, and stress in chronic musculoskeletal pain. *Arch Phys Med Rehabil*. 2011;92(12):2041–2056.
18. Gaab J, Baumann S, Budnoik A, Gmunder H, Hottinger N, Ehlert U. Reduced reactivity and enhanced negative feedback sensitivity of the hypothalamus-pituitary-adrenal axis in chronic whiplash-associated disorder. *Pain*. 2005;119(1–3):219–224.
19. Sullivan MJ, Thibault P, Simmonds MJ, Milioto M, Cantin AP, Velly AM. Pain, perceived injustice and the persistence of post-traumatic stress symptoms during the course of rehabilitation for whiplash injuries. *Pain*. 2009;145(3):325–331.
20. Walton DM, Elliott JM. An Integrated Model of Chronic Whiplash-Associated Disorder. *J Orthop Sports Phys Ther*. 2017;47(7):462–471.
21. Pedler A, Sterling M. Patients with chronic whiplash can be sub-grouped on the basis of symptoms of sensory hypersensitivity and posttraumatic stress. *Pain*. 2013;154(9):1640–1648.
22. Campbell L, Smith A, McGregor L, Sterling M. Psychological factors and the development of chronic whiplash-associated disorder(s): a systematic review. *Clin J Pain*. 2018;34(8):755–768.
23. Hannibal KE, Bishop MD. Chronic stress, cortisol dysfunction, and pain: a psychoneuroendocrine rationale for stress management in pain rehabilitation. *Phys Ther*. 2014;94(12):1816–1825.
24. Nijs J, Leysen L, Vanlauwe J, Logghe T, Ickmans K, Polli A, et al. Treatment of central sensitization in patients with chronic pain: time for change? *Expert Opin Pharmacother*. 2019;1–10.
25. Nijs J, Lluch Girbes E, Lundberg M, Malfliet A, Sterling M. Exercise therapy for chronic musculoskeletal pain: innovation by altering pain memories. *Man Ther*. 2015;20(1):216–220.
26. Malfliet A, Kregel J, Coppieters I, De Pauw R, Meeus M, Roussel N, et al. Effect of pain neuroscience education combined with cognition-targeted motor control training on chronic spinal pain: a randomized clinical trial. *JAMA Neurol*. 2018;75(7):808–817.
27. Moseley GL. Widespread brain activity during an abdominal task markedly reduced after pain physiology education: fMRI evaluation of a single patient with chronic low back pain. *Aust J Physiother*. 2005;51(1):49–52.
28. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200–207.
29. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med*. 2010;8:18.
30. Butler D, Moseley GL. *Explain pain*. Adelaide: NOI Group Publishing; 2003, 116p.
31. Van Wilgen C, Nijs J. *Pijneducatie: een praktische handleiding voor (para)medici: Bohn Stafleu van Loghum*; 2010.
32. Nijs J, Paul van Wilgen C, Van Oosterwijck J, van Ittersum M, Meeus M. How to explain central sensitization to patients with 'unexplained' chronic musculoskeletal pain: practice guidelines. *Man Ther*. 2011;16(5):413–418.
33. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2005;113(1–2):9–19.
34. Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA. Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain? *Pain Med*. 2001;2(4):309–316.
35. MacDermid JC, Walton DM, Avery S, Blanchard A, Etruw E, McAlpine C, et al. Measurement properties of the neck disability index: a systematic review. *J Orthop Sports Phys Ther*. 2009;39(5):400–417.
36. Vernon H. The Neck Disability Index: state-of-the-art, 1991–2008. *J Manipulative Physiol Ther*. 2008;31(7):491–502.
37. Jorritsma W, de Vries GE, Dijkstra PU, Geertzen JH, Reneman MF. Neck Pain and Disability Scale and Neck Disability Index: validity of Dutch language versions. *Eur Spine J*. 2012;21(1):93–100.
38. Jorritsma W, de Vries GE, Geertzen JH, Dijkstra PU, Reneman MF. Neck Pain and Disability Scale and the Neck Disability Index: reproducibility of the Dutch Language Versions. *Eur Spine J*. 2010;19(10):1695–1701.
39. Ware JESKMM, Gandek B. *SF-36 Health Survey Manual and Interpretation Guide*. Boston, MA: New England Medical Center, the Health Institute; 1993.
40. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*. 1993;31(3):247–263.
41. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *J Clin Epidemiol*. 1998;51(11):1055–1068.
42. Cleland JA, Childs JD, Whitman JM. Psychometric properties of the Neck Disability Index and Numeric Pain Rating Scale in patients with mechanical neck pain. *Arch Phys Med Rehabil*. 2008;89(1):69–74.

43. Kregel J, Vuijk PJ, Descheemaeker F, Keizer D, van der Noord R, Nijs J, et al. The Dutch Central Sensitization Inventory (CSI): factor analysis, discriminative power and test-retest reliability. *Clin J Pain*. 2015.
44. Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the central sensitization inventory. *Pain Pract*. 2012;12(4):276–285.
45. Cuesta-Vargas AI, Neblett R, Chiarotto A, Kregel J, Nijs J, van Wilgen CP, et al. Dimensionality and reliability of the central sensitization inventory in a pooled multicountry sample. *J Pain*. 2018;19(3):317–329.
46. Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the central sensitization inventory: a systematic review. *Pain Pract*. 2018;18(4):544–554.
47. Goudman L, Huysmans E, Coppieters I, Ickmans K, Nijs J, Buyl R, et al. Electrical (Pain) thresholds and conditioned pain modulation in patients with low back-related leg pain and patients with failed back surgery syndrome: a cross-sectional pilot study. *Pain Med*. 2019.
48. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. *Pain*. 2002;99(1–2):49–59.
49. Cathcart S, Winefield AH, Rolan P, Lushington K. Reliability of temporal summation and diffuse noxious inhibitory control. *Pain Res Manag*. 2009;14(6):433–438.
50. Lewis GN, Rice DA, McNair PJ. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. *J Pain*. 2012;13(10):936–944.
51. France CR, France JL, al'Absi M, Ring C, McIntyre D. Catastrophizing is related to pain ratings, but not nociceptive flexion reflex threshold. *Pain*. 2002;99(3):459–463.
52. Motohashi K, Umino M. Heterotopic painful stimulation decreases the late component of somatosensory evoked potentials induced by electrical tooth stimulation. *Brain Res Cogn Brain Res*. 2001;11(1):39–46.
53. Terkelsen AJ, Andersen OK, Hansen PO, Jensen TS. Effects of heterotopic- and segmental counter-stimulation on the nociceptive withdrawal reflex in humans. *Acta Physiol Scand*. 2001;172(3):211–217.
54. Savic G, Bergstrom EM, Frankel HL, Jamous MA, Ellaway PH, Davey NJ. Perceptual threshold to cutaneous electrical stimulation in patients with spinal cord injury. *Spinal Cord*. 2006;44(9):560–566.
55. Nickel FT, DeCol R, Jud S, Fasching PA, Seifert F, Maihofner C. Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. *Pain*. 2011;152(6):1298–1303.
56. Vuilleumier PH, Biurrun Manresa JA, Ghamri Y, Mlekusch S, Siegenthaler A, Arendt-Nielsen L, et al. Reliability of quantitative sensory tests in a low back pain population. *Reg Anesth Pain Med*. 2015;40(6):665–673.
57. Banic B, Petersen-Felix S, Andersen OK, Radanov BP, Viliger PM, Arendt-Nielsen L, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. *Pain*. 2004;107(1–2):7–15.
58. Goudman L, Laton J, Brouns R, Nagels G, Huysmans E, Buyl R, et al. Cortical mapping of painful electrical stimulation by quantitative electroencephalography: unraveling the time-frequency-channel domain. *J Pain Res*. 2017;10:2675–2685.
59. Biurrun Manresa JA, Neziri AY, Curatolo M, Arendt-Nielsen L, Andersen OK. Test-retest reliability of the nociceptive withdrawal reflex and electrical pain thresholds after single and repeated stimulation in patients with chronic low back pain. *Eur J Appl Physiol*. 2011;111(1):83–92.
60. Piche M, Watanabe N, Sakata M, Oda K, Toyohara J, Ishii K, et al. Basal mu-opioid receptor availability in the amygdala predicts the inhibition of pain-related brain activity during heterotopic noxious counter-stimulation. *Neurosci Res*. 2014;81-82:78–84.
61. Fujii-Abe K, Oono Y, Motohashi K, Fukayama H, Umino M. Heterotopic CO₂ laser stimulation inhibits tooth-related somatosensory evoked potentials. *Pain Med*. 2010;11(6):825–833.
62. Lewis GN, Heales L, Rice DA, Rome K, McNair PJ. Reliability of the conditioned pain modulation paradigm to assess endogenous inhibitory pain pathways. *Pain Res Manag*. 2012;17(2):98–102.
63. Kennedy DL, Kemp HI, Ridout D, Yarnitsky D, Rice AS. Reliability of conditioned pain modulation: a systematic review. *Pain*. 2016;157(11):2410–2419.
64. Van Damme S, Crombez G, Bijttebier P, Goubert L, Van Houdenhove B. A confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor structure across clinical and non-clinical populations. *Pain*. 2002;96(3):319–324.
65. Leysen M, Nijs J, Meeus M, Paul van Wilgen C, Struyf F, Vermandel A, et al. Clinimetric properties of illness perception questionnaire revised (IPQ-R) and brief illness perception questionnaire (Brief IPQ) in patients with musculoskeletal disorders: a systematic review. *Man Ther*. 2015;20(1):10–17.
66. Weiss DS, Marmar CR. The impact of event scale-revised. In: Wilson JP, Keane TM, eds. *Assessing Psychological Trauma and PTSD*. 2001.
67. Weiss D, Marmar C. In: Wilson P, Keane T, eds. *Assessing psychological trauma and post traumatic stress disorder: a handbook for practitioners*. New York: Guilford Press; 1997.
68. Roelofs J, McCracken L, Peters ML, Crombez G, van Breukelen G, Vlaeyen JW. Psychometric evaluation of the Pain Anxiety Symptoms Scale (PASS) in chronic pain patients. *J Behav Med*. 2004;27(2):167–183.
69. McCracken LM, Dhingra L. A short version of the Pain Anxiety Symptoms Scale (PASS-20): preliminary development and validity. *Pain Res Manag*. 2002;7(1):45–50.
70. Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. *Handleiding iMTA Medical cost Questionnaire (iMCQ)*; 2013.
71. Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. *Handleiding iMTA Productivity Cost Questionnaire (iPCQ)*; 2013.
72. Tan SS, Teirlinck CH, Dekker J, Goossens LM, Bohnen AM, Verhaar JA, et al. Cost-utility of exercise therapy in patients with hip osteoarthritis in primary care. *Osteoarthritis Cartilage*. 2016;24(4):581–588.
73. Pool JJ, Ostelo RW, Hoving JL, Bouter LM, de Vet HC. Minimal clinically important change of the Neck Disability Index and the Numerical Rating Scale for patients with neck pain. *Spine (Phila Pa 1976)*. 2007;32(26):3047–3051.
74. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. 2008;9(2):105–121.
75. Spitzer WO, Skovron ML, Salmi LR, Cassidy JD, Duranceau J, Suissa S, et al. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining “whiplash” and its management. *Spine (Phila Pa 1976)*. 1995;20(8 Suppl):1s–73s.
76. Sterling M. A proposed new classification system for whiplash associated disorders – implications for assessment and management. *Man Ther*. 2004;9(2):60–70.
77. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devreux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Bmj*. 2010;340:c869.